Background
==========

Graves\' disease (GD) is an organ-specific autoimmune thyroid disease \[[@B1]\]. It has been known that multiple factors, including the host\'s genetic factors as well as environmental factors, contribute to the etiology and severity of GD \[[@B2],[@B3]\]. However, other forms of variation that might affect gene expression should also be considered.

A new paradigm in human genetics is high frequencies of interindividual variation in the copy number (CN) of specific genomic DNA segments. Copy number variation (CNV) loci often contain genes engaged in host-environment interactions, including those involved in immune functions, which results in susceptibility or resistance to autoimmune diseases \[[@B4]-[@B7]\], however, no significant association has been found between CNV and GD \[[@B6]\].

*Complement component C4*(*C4*), located on chromosome 6q21.3, is encoded by 2 separate loci in the major histocompatibility complex class III region and derives 2 functionally distinct *C4A*and *C4B*isoforms \[[@B8]\]. The complement system is the main element of innate immunity and is regarded as the first line of defense against intrinsic and extrinsic antigens, leading to peptide-mediated inflammation, opsonization leading phagocytosis, the direct lysis of antigens \[[@B9]\]. Presuming a major role of complement as an effecter in peptide-mediated inflammation and phagocytosis, we hypothesized that *C4*genetic diversity may partially explain the development of GD as well as the variation in its outcomes. Here we investigated the polymorphic variants of *C4*that correlate with predisposition to this disease.

Methods
=======

Patients and healthy individuals
--------------------------------

A total of 624 patients (227 with GO and 397 without GO) with a confirmed diagnosis of GD and an appropriate control group with 160 healthy volunteers from China Medical University Hospital in Taiwan were enrolled and followed actively. All individuals provided informed consent as approved by the ethics committee of China Medical University Hospital. For the patients, diagnosis of GD and GO was followed the criteria set previously \[[@B10]\]. Full medical record abstraction was conducted to obtain demographics (age and gender); treatment and clinical features are summarized in Table [1](#T1){ref-type="table"}. For the healthy individuals, those with matched for gender according to the female predominance of GD including 32 male (20.0%) and 128 female (80.0%). Age was different in healthy (27.4 ± 6.4 years) as compared to the patients with GD (41.1 ± 12.9 years) (p = 1.96 × 10^-34^).

###### 

Background and demographic characteristics of patients with Graves\' disease

  Patients\' characteristics   Healthy (160)   GD (624)     Myxedema     P-value     GO                P-value      Vitiligo     P-value                                     
  ---------------------------- --------------- ------------ ------------ ----------- ----------------- ------------ ------------ ----------------- ------------ ------------ -----------------
  **Age at diagnosis**                                                                                                                                                       
  ≤ 40                         145 (90.6)      307 (49.2)   247 (47.0)   59 (60.2)   0.017             182 (45.8)   125 (55.1)   0.027             239 (46.9)   68 (59.6)    0.014
  \> 40                        15 (9.4)        317 (50.8)   278 (53.0)   39 (39.8)                     215 (54.2)   102 (44.9)                     271 (53.1)   46 (40.4)    
  **Gender**                                                                                                                                                                 
  Male                         32 (20.0)       133 (21.3)   110 (21.0)   22 (22.4)   0.739             74 (18.6)    59 (26.0)    0.031             107 (21.0)   26 (22.8)    0.700
  Female                       128 (80.0)      491 (78.7)   415 (79.0)   76 (77.6)                     323 (81.4)   168 (74.0)                     403 (79.0)   88 (77.2)    
  **Treatment**                                                                                                                                                              
  Radioiodine                                                                                                                                                                
  No                                           601 (96.3)   504 (96.0)   96 (98.0)   0.345             389 (98.0)   212 (93.4)   0.003             489 (95.9)   112 (98.2)   0.226
  Yes                                          23 (3.7)     21 (4.0)     2 (2.0)                       8 (2.0)      15 (6.6)                       21 (4.1)     2 (1.8)      
  Thyroid gland surgery                                                                                                                                                      
  No                                           564 (90.4)   472 (89.9)   91 (92.9)   0.363             363 (91.4)   201 (88.5)   0.239             457 (89.6)   107 (93.9)   0.164
  Yes                                          60 (9.6)     53 (10.1)    7 (7.1)                       34 (8.6)     26 (11.5)                      53 (10.4)    7 (6.1)      
  **Clinical features**                                                                                                                                                      
  Goiter                                                                                                                                                                     
  Grade 1-3                                    146 (23.5)   119 (22.8)   27 (27.6)   0.309             101 (25.5)   46 (20.4)    0.154             117 (23.1)   30 (26.3)    0.462
  Grade 4-5                                    474 (76.5)   403 (77.2)   71 (72.4)                     295 (74.5)   179 (79.6)                     390 (76.9)   84 (73.7)    
  Nodular hyperplasia                                                                                                                                                        
  No                                           483 (77.5)   434 (82.7)   49 (50.5)   2.880 × 10^-12^   301 (75.8)   182 (80.5)   0.175             430 (84.3)   53 (46.9)    6.670 × 10^-18^
  Yes                                          140 (22.5)   91 (17.3)    49 (49.5)                     96 (24.2)    44 (19.5)                      80 (15.7)    60 (53.1)    
  Myxedema                                                                                                                                                                   
  No                                           525 (74.3)                                              305 (76.8)   220 (97.3)   1.35 × 10^-11^    507 (99.4)   18 (15.9)    8.900 × 10^-8^
  Yes                                          98 (25.7)                                                            92 (23.2)    6 (2.7)                        3 (0.6)      95 (84.1)
  Graves\' ophthalmopathy                                                                                                                                                    
  No                                           397 (63.6)   305 (58.0)   92 (93.9)   1.350 × 10^-11^                                               295 (57.8)   102 (89.5)   2.200 × 10^-10^
  Yes                                          227 (36.4)   220 (41.9)   6 (6.1)                                                                   215 (42.2)   12 (10.5)    
  Vitiligo                                                                                                                                                                   
  No                                           510 (81.7)   507 (96.6)   3 (3.1)     8.900 × 10^-8^    295 (74.3)   215 (94.7)   2.204 × 10^-10^                             
  Yes                                          114 (18.3)   18 (3.4)     95 (96.9)                     102 (25.7)   12 (5.3)                                                 

Abbreviations: GD, Graves, disease; GO, Graves\' ophthalmopathy; SD, standard deviation; N, number.

Genomic DNA extraction and quantification gene dosage of *C4A*and *C4B*
-----------------------------------------------------------------------

Genomic DNA was extracted from peripheral blood following the manufactory\'s suggestions (Qiagen). *C4*gene dosage was assessed by quantitative real-time TaqMan^®^PCR analysis (Applied Biosystems) as described in the previously published protocols with some modification \[[@B11]\]. Real-time PCR analysis was performed in 96-well optical plates on a 7900HT real-time PCR system (Applied Biosystems). Primers and probes specific for *C4A*, and *C4B*(common *C4A*and *C4B*forward primer \"C4F\": 5\'-GCA GGA GAC ATC TAA CTG GCT TCT-3\'; common *C4A*and *C4B*reverse primer \"C4R\": 5\'-CCG CAC CTG CAT GCT CCT-3\'; probe \"*C4A*\": FAM-ACC CCT GTC CAG TGT TAG; probe \"*C4B*\": FAM-ACC TCT CTC CAG TGA TAC. TaqMan^®^Universal PCR Master Mix, No AmpErase^®^uracil-DNA glycosylase (ABI catalog number 4326614), VIC-conjugated TaqMan^®^*RNase P*control reagents (ABI catalog number 4316844), 250 nM of the respective FAM-conjugated TaqMan^®^probes (*C4A*or *C4B*), the particular primers (300 nM *C4A*or *C4B*) in distilled water was contained in each of the distinct PCR batches. Appropriately prediluted genomic DNA (threshold cycle \[C~T~\] values for *RNase P*between 24 and 30) was added before start. CN of each target gene in each sample was determined from three separated experiments. Thermal cycler conditions were adjusted as follows: initial denaturation step for 10 minutes at 95°C; 40 cycles including denaturation for 15 seconds at 95 °C; and annealing/extension for 1 minute for 60°C. The data were analyzed using SDS 2.3 software (Applied Biosystems).

The C~T~value of *RNase P*, *C4A*or *C4B*was converted into a raw gene dosage by the formula nRAW~*C4X*~= 2 ^(CT*RNase\ P*)-(CT*C4X*)+1^, where *C4X*referred to *C4A*or *C4B*. Raw gene dosages of positive controls selected from the reference panel were plotted versus the actual gene dosages, and the resulting calibration curve served for determination of the actual copy number of unknown samples of this particular run.

Statistical analysis
--------------------

Statistical analysis was performed using the statistical package PASW for Windows (version 18.0; SPSS Inc.). The demographics of patients and healthy individuals were analyzed by the chi-square analysis. For those with 2 × 2 contingency tables, differences in the incidence of individuals with *C4*gene CNs above and below the median or *C4A-C4B*polymorphisms between patients with or without indicated feature were evaluated using Fisher\'s exact test. For those above 2 × 2 contingency tables, differences in the incidence of individuals with *C4*gene CNs above and below the median or *C4A-C4B*polymorphisms between patients with or without indicated feature were evaluated using Fisher\'s exact test, and the two-tailed *p*value was estimated by 100,000 Monte Carlo simulations with 99% confidence intervals (CI) (99% confidence for the simulation result). Odds ratios (ORs) and 95% CIs were estimated from logistic regression models adjusting for confounding variables as shown in Table [1](#T1){ref-type="table"}.

Results
=======

CNV of *C4*genes is associated with susceptibility to GD
--------------------------------------------------------

The distribution of copy number for total *C4*, *C4*isotypes as well as *C4*polymorphisms according to the presence of GD is shown in Table [2](#T2){ref-type="table"}. No individuals had a full deficiency of *C4*alleles. After adjusting for age, individuals with 4 copies of *C4*gene were more susceptible to GD (*p*= 0.001, OR = 10.994, 95% CI: 6.277-19.255) as compared to those without, whereas those with \<4 copies of *C4*gene tended to prevent from GD (*p*= 0.003, OR = 0.512, 95% CI: 0.338-0.776) as compared to those without. The distribution of *C4A*and *C4B*among individuals with or without GD was further investigated. For *C4A*gene, individuals with 2 copies of *C4A*increased the risk toward GD (*p*= 0.008, OR = 1.732, 95% CI: 1.190-2.520) whereas those with \<2 copies of *C4A*reduced the risk toward GD (*p*= 0.01, OR = 0.584, 95% CI: 0.360-0.948). For *C4B*gene, individuals with 2 copies of *C4B*increased the risk toward GD (*p*= 2.420 × 10^-5^, OR = 2.621, 95% CI: 1.791-3.835) whereas those without 2 copies of *C4B*reduced the risk toward GD (*p*= 0.008, OR = 0.487, 95% CI: 0.322-0.738 for those with \<2 copies *C4B*; *p*= 0.015, OR = 0.545, 95% CI: 0.347-0.856 for those with \>2 copies *C4B*respectively). Polymorphism analysis indicated tat individuals with the most common polymorphism (37.3%), A2B2, with 2.671-fold risk toward GD (*p*= 1.395 × 10^-4^, OR = 2.671, 95% CI: 1.761-4.052) as compared to those without. These results indicate that individuals with 4, 2 and 2 copies of *C4*, *C4A*and *C4B*genes, especially those with A2B2 polymorphism may have higher risk, whereas those with\<4, \<2 and ≠2 copies of *C4*, *C4A*and *C4B*genes may have lower risk toward GD, respectively.

###### 

Distribution of *C4*polymorphisms in individuals with or without Graves\' disease

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------
  Variations              GD          ***P*value, individual**^**a**^\        ***P*value**^**b**^                     **OR (95%CI)**^**d**^   
                                      **\[OR (95%CI), individual\]**^**c**^                                                                   
  ----------------------- ----------- --------------------------------------- --------------------------------------- ----------------------- ---------------------
  ***C4*CNV**                                                                                                                                 

  4                       57 (35.6)   314 (50.3)                              0.001 \[10.994 (6.277-19.255)\]         0.002                   (Reference)

  \< 4                    52 (32.5)   134 (21.5)                              0.003 \[0.512 (0.338-0.776)\]                                   0.389 (0.245-0.615)

  \> 4                    51 (31.9)   176 (28.2)                              0.361                                                           0.497 (0.317-0.780)

  ***C4A*CNV**                                                                                                                                

  2                       83 (51.9)   395 (63.3)                              0.008 \[1.732 (1.190-2.520)\]           0.011                   (Reference)

  \< 2                    33 (20.6)   79 (12.7)                               0.010 \[0.584 (0.360-0.948)\]                                   0.509 (0.307-0.843)

  \> 2                    44 (27.5)   150 (24.0)                              0.365                                                           0.628 (0.404-0.977)

  ***C4B*CNV**                                                                                                                                

  2                       67 (41.9)   377 (60.4)                              2.420 × 10^-5^\[2.621 (1.791-3.835)\]   1.328 × 10^-4^          (Reference)

  \< 2                    53 (33.1)   143 (22.9)                              0.008 \[0.487 (0.322-0.738)\]                                   0.374 (0.240-0.584)

  \> 2                    40 (25)     104 (16.7)                              0.015 \[0.545 (0.347-0.856)\]                                   0.391 (0.241-0.636)

  ***C4*polymorphisms**                                                                                                                       

  A2B2                    39 (24.4)   254 (40.7)                              1.395 × 10^-4^\[2.671 (1.761-4.052)\]   3.87 × 10^-6^           (Reference)

  A2B1                    22 (13.8)   78 (12.5)                               0.672                                                           0.409 (0.219-0.763)

  A3B2                    16 (10.0)   64 (10.3)                               0.924                                                           0.539 (0.273-1.064)

  A2B3                    5 (3.1)     44 (7.1)                                0.067                                                           0.961 (0.343-2.697)

  A3B1                    10 (6.3)    32 (5.1)                                0.574                                                           0.373 (0.159-0.876)

  A1B2                    6 (3.8)     34 (5.4)                                0.384                                                           0.687 (0.257-1.836)

  Other                   62 (38.8)   118 (18.9)                                                                                              0.242 (0.148-0.396)
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------

Abbreviations: GD, Graves\' disease; CNV, copy number variation; OR, odds ratio; CI, confidence interval; N, number.

^a^Individual *C4*CNVs and polymorphisms between individuals with or without GD were evaluated by Fisher\'s exact test using 2 × 2 contingency tables.

^b^CNV of *C4, C4A and C4B*between individuals with or without GD were evaluated by Fisher\'s exact test using 3 × 2 contingency tables.*C4*polymorphisms between individuals with or without GD were evaluated by Fisher\'s exact test using 7 × 2 contingency tables. The *p*value was estimated by 100,000 Monte Carlo simulations with 99% confidence intervals (CI).

^c^ORs and 95% CIs were estimated from logistic regression models adjusting for age.

^d^ORs and 95% CIs were estimated from logistic regression models adjusting for age.

CNV of *C4*genes did not significantly associated with myxedema and GO
----------------------------------------------------------------------

We also estimated the association between polymorphism of *C4*genes and clinical features of GD. CNV of *C4*genes showed association with susceptibility toward GO, vitiligo and myxedema, but not goiter or nodular hyperplasia as estimated by Fisher\'s exert test (data not shown). After adjusting for age, nodular hyperplasia, GO, and vitiligo, the distribution of copy number for total *C4*, *C4*isotypes as well as *C4*polymorphisms did not associate with the occurrence of myxedema (Table [3](#T3){ref-type="table"}).

###### 

Distribution of *C4*polymorphisms in Graves\' disease patients with or without myxedema

  -----------------------------------------------------------------------------------------------------------------------------------------------------------
  Variations              Myxedema     ***P*value, individual**^**a**^\        ***P*value**^**b**^             **OR (95%CI)**^**d**^   
                                       **\[OR (95%CI), individual\]**^**c**^                                                           
  ----------------------- ------------ --------------------------------------- ------------------------------- ----------------------- ----------------------
  ***C4*CNV**                                                                                                                          

  4                       265 (50.5)   48 (49.0)                               0.826                                                   (Reference)

  \< 4                    100 (19.0)   34 (34.7)                               0.001 \[1.884 (0.538-6.597)\]   4.900 × 10^-4^          1.714 (0.447-6.575)

  \> 4                    160 (30.5)   16 (16.3)                               0.005 \[0.617 (0.166-2.289)\]                           0.761 (0.186-3.122)

  ***C4A*CNV**                                                                                                                         

  2                       336 (64.0)   58 (59.2)                               0.364                                                   (Reference)

  \< 2                    57 (10.9)    22 (22.5)                               0.003 \[0.627 (0.164-2.404)\]   0.008                   0.511 (0.122-2.134)

  \> 2                    132 (25.1)   18 (18.4)                               0.159                                                   0.496 (0.117-2.106)

  ***C4B*CNV**                                                                                                                         

  2                       317 (60.4)   59 (60.2)                               1                                                       (Reference)

  \< 2                    115 (21.9)   28 (28.6)                               0.152                           0.168                   1.163 (0.298-4.542)

  \> 2                    93 (17.7)    11 (11.2)                               0.072                                                   0.552 (0.125-2.443)

  ***C4*polymorphisms**                                                                                                                

  A2B2                    217 (41.3)   36 (36.7)                               0.434                           0.050                   (Reference)

  A2B1                    63 (12.0)    15 (15.3)                               0.405                                                   1.895 (0.307-11.710)

  A3B2                    58 (11.0)    6 (6.1)                                 0.202                                                   1.371 (0.163-11.522)

  A2B3                    41 (7.8)     3 (3.1)                                 0.130                                                   0.558 (0.029-10.789)

  A3B1                    26 (5.0)     6 (6.1)                                 0.619                                                   0.333 (0.032-3.499)

  A1B2                    23 (4.4)     11 (11.2)                               0.013 \[1.094 (0.137-8.709)\]                           1.009 (0.103-9.841)

  Other                   97 (18.5)    21 (21.4)                                                                                       0.735 (0.163-3.310)
  -----------------------------------------------------------------------------------------------------------------------------------------------------------

Abbreviations: GD, Graves\' disease; GO, Graves\' ophthalmopathy; CNV, copy number variation; OR, odds ratio; CI, confidence interval; N, number.

^a^Individual *C4*CNVs and polymorphisms between GD patients with or without myxedema were evaluated by Fisher\'s exact test using 2 × 2 contingency tables.

^b^CNV of *C4, C4A and C4B*between GD patients with or without myxedema were evaluated by Fisher\'s exact test using 3 × 2 contingency tables.*C4*polymorphisms between GD patients with or without myxedema were evaluated by Fisher\'s exact test using 7 × 2 contingency tables. The *p*value was estimated by 100,000 Monte Carlo simulations with 99% confidence intervals (CI).

^c^ORs and 95% CIs were estimated from logistic regression models adjusting for age, nodular hyperplasia, GO and vitiligo.

^d^ORs and 95% CIs were estimated from logistic regression models adjusting for age, nodular hyperplasia, GO and vitiligo.

The distribution of copy number for total *C4*, *C4*isotypes as well as *C4*polymorphisms according to the presence of GO is shown in Table [4](#T4){ref-type="table"}. The relationship between *C4*CNV status and GO was not significant (*p*= 0.396). The distribution of *C4A*and *C4B*among GD patients with and without GO were further investigated. After adjusting for age, gender, radioiodine treatment, vitiligo and myxedema, neither isotypes nor polymorphisms of *C4*was significantly associated with GO, although GD patients with \<2 copies (0 or 1) of the *C4A*gene were less susceptible to GO (*p*= 0.014, OR = 0.549, 95% CI: 0.303-0.998) as compared to those with 2 copies of *C4A*, and those with A3B1 polymorphism were less susceptible to GO (*p*= 0.001, OR = 0.374, 95% CI: 0.146-0.960) as compared to those with A2B2 polymorphism. These results indicate that neither isotypes nor polymorphisms of *C4*was significantly associated with GO, however, as compared to GD patients with 2 copies of *C4A*or those with A2B2 polymorphism, those with \<2 copies of *C4A*or those with A3B1 might be protected against the development of GO, respectively.

###### 

Distribution of *C4*polymorphisms in Graves\' disease patients with or without Graves\' ophthalmopathy

  ----------------------------------------------------------------------------------------------------------------------------------------------------------
  Variations              GO           ***P*value, individual**^**a**^\        ***P*value**^**b**^             **OR (95%CI)**^**d**^   
                                       **\[OR (95%CI), individual\]**^**c**^                                                           
  ----------------------- ------------ --------------------------------------- ------------------------------- ----------------------- ---------------------
  ***C4*CNV**                                                                                                                          

  4                       196 (49.4)   118 (52.0)                              0.561                           0.396                   (Reference)

  \< 4                    92 (23.2)    42 (18.5)                               0.188                                                   0.978(0.614-1.558)

  \> 4                    109 (27.5)   67 (29.5)                               0.581                                                   1.029(0.687-1.540)

  ***C4A*CNV**                                                                                                                         

  2                       238 (39.9)   157 (69.2)                              0.025 \[1.436 (0.994-2.075)\]   0.014                   (Reference)

  \< 2                    61 (15.4)    18 (7.9)                                0.008 \[0.590 (0.328-1.059)\]                           0.549 (0.303-0.998)

  \> 2                    98 (24.7)    52 (22.9)                               0.628                                                   0.772 (0.509-1.169)

  ***C4B*CNV**                                                                                                                         

  2                       229 (57.7)   148 (65.2)                              0.074                           0.186                   (Reference)

  \< 2                    97 (24.4)    46 (20.3)                               0.276                                                   0.806 (0.520-1.249)

  \> 2                    71 (17.9)    33 (14.5)                               0.316                                                   0.697 (0.430-1.132)

  ***C4*polymorphisms**                                                                                                                

  A2B2                    149 (37.5)   105 (46.3)                              0.035 \[1.283 (0.900-1.828)\]   0.005                   (Reference)

  A2B1                    53 (13.4)    25 (11.0)                               0.451                                                   0.796 (0.449-1.411)

  A3B2                    37 (9.3)     27 (11.9)                               0.338                                                   1.067 (0.596-1.912)

  A2B3                    29 (7.3)     15 (6.6)                                0.871                                                   0.734 (0.366-1.476)

  A3B1                    25 (6.3)     7 (3.1)                                 0.091                                                   0.374 (0.146-0.960)

  A1B2                    28 (7.1)     6 (2.6)                                 0.026 \[0.451(0.176-1.160)\]                            0.374 (0.153-1.056)

  Other                   65 (16.4)    40 (17.6)                                                                                       0.894 (0.549-1.455)
  ----------------------------------------------------------------------------------------------------------------------------------------------------------

Abbreviations: GD, Graves\' disease; GO, Graves\' ophthalmopathy; CNV, copy number variation; OR, odds ratio; CI, confidence interval; N, number.

^a^Individual *C4*CNVs and polymorphisms between GD patients with or without GO were evaluated by Fisher\'s exact test using 2 × 2 contingency tables.

^b^CNV of *C4, C4A and C4B*between GD patients with or without GO were evaluated by Fisher\'s exact test using 3 × 2 contingency tables.*C4*polymorphisms between GD patients with or without GO were evaluated by Fisher\'s exact test using 7 × 2 contingency tables. The *p*value was estimated by 100,000 Monte Carlo simulations with 99% confidence intervals (CI).

^c^ORs and 95% CIs were estimated from logistic regression models adjusting for age, gender, ever received radioiodine treatment, myxedema and vitiligo.

^d^ORs and 95% CIs were estimated from logistic regression models adjusting for age, gender, ever received radioiodine treatment, myxedema and vitiligo.

GD patients with \<2 copies of *C4A*had higher risk toward vitiligo
-------------------------------------------------------------------

The distribution of copy number for total *C4*, *C4*isotypes as well as *C4*polymorphisms according to the presence of vitiligo is shown in Table [4](#T4){ref-type="table"}. After adjusting with age, nodular hyperplasia, GO and myxedema, patients with \<2 copies of *C4A*had a 5.153-fold increased risk of vitiligo (*p*= 2.650 × 10^-4^, OR = 5.153, 95% CI: 1.629-16.300). It remained significant even when compared with GD patients with 2 copies of *C4A*(*p*= 0.001, OR = 5.579, 95% CI: 1.659-18.763, Table [5](#T5){ref-type="table"}). These results indicate that \<2 copies of *C4A*may increase the risk for vitiligo in patients with GD.

###### 

Distribution of *C4*polymorphisms in Graves\' disease patients with or without vitiligo

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Variations              Vitiligo     ***P*value, individual**^**a**^\        ***P*value**^**b**^                      **OR (95%CI)**^**d**^   
                                       **\[OR (95%CI), individual\]**^**c**^                                                                    
  ----------------------- ------------ --------------------------------------- ---------------------------------------- ----------------------- ----------------------
  ***C4*CNV**                                                                                                                                   

  4                       258 (50.6)   56 (49.1)                               0.836                                    0.002                   (Reference)

  \< 4                    97 (19.0)    37 (32.5)                               0.002 \[1.297 (0.434-3.874)\]                                    1.334 (0.415-4.289)

  \> 4                    155 (30.4)   21 (18.4)                               0.011 \[0.987 (0.362-2.691)\]                                    1.076 (0.370-3.133)

  ***C4A*CNV**                                                                                                                                  

  2                       330 (64.7)   65 (57.0)                               0.133                                                            (Reference)

  \< 2                    52 (10.2)    27 (23.7)                               2.650 × 10^-4^\[5.153 (1.629-16.3000\]   0.001                   5.579 (1.659-18.763)

  \> 2                    128 (25.1)   22 (19.3)                               0.225                                                            1.289 (0.414-4.013)

  ***C4B*CNV**                                                                                                                                  

  2                       310 (60.8)   67 (58.8)                               0.751                                                            (Reference)

  \< 2                    112 (22.0)   31 (27.2)                               0.267                                    0.414                   1.133 (0.355-3.614)

  \> 2                    88 (17.3)    16 (14.0)                               0.487                                                            2.107 (0.687-6.467)

  ***C4*polymorphisms**                                                                                                                         

  A2B2                    213 (41.8)   41 (36.0)                               0.292                                    0.03                    (Reference)

  A2B1                    62 (12.2)    16 (14.0)                               0.638                                                            0.889 (0.175-4.524)

  A3B2                    57 (11.2)    7 (6.1)                                 0.125                                                            0.756 (0.132-4.335)

  A2B3                    40 (7.8)     4 (3.5)                                 0.154                                                            1.111 (0.151-8.205)

  A3B1                    25 (4.9)     7 (6.1)                                 0.638                                                            1.484 (0.199-11.089)

  A1B2                    22 (4.3)     12 (10.5)                               0.019 \[2.035(0.335-12.368)\]                                    2.745 (0.384-19.599)

  Other                   91 (17.8)    27 (23.7)                                                                                                3.471 (1.046-11.525)
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------

Abbreviations: GD, Graves\' disease; GO, Graves\' ophthalmopathy; CNV, copy number variation; OR, odds ratio; CI, confidence interval; N, number.

^a^Individual *C4*CNVs and polymorphisms between GD patients with or without vitiligo were evaluated by Fisher\'s exact test using 2 × 2 contingency tables.

^b^CNV of *C4, C4A and C4B*between GD patients with or without vitiligo were evaluated by Fisher\'s exact test using 3 × 2 contingency tables.*C4*polymorphisms between GD patients with or without vitiligo were evaluated by Fisher\'s exact test using 7 × 2 contingency tables. The *p*value was estimated by 100,000 Monte Carlo simulations with 99% confidence intervals (CI).

^c^ORs and 95% CIs were estimated from logistic regression models adjusting for age, nodular hyperplasia, myxedema and GO.

^d^ORs and 95% CIs were estimated from logistic regression models adjusting for age, nodular hyperplasia, myxedema and GO.

Discussion
==========

Several functionally relevant single nucleotide polymorphisms are characteristic of GD and GO \[[@B12],[@B13]\], but no relevant CNV has been reported \[[@B14]\]. In the present study, we found that the CNV of *C4*, *C4A*or *C4B*may associate with the development of GD. In addition, \<2 copies of *C4A*may associate with development of vitiligo in patients with GD. To the best of our knowledge, this is the first study to report that the linkage among CNV of *C4*genes, GD and GD-associated vitiligo. Our results provide new information which may be applied clinically.

C4 involves in the classical pathway which is triggered by interaction of the Fc portion of an antibody or C-reactive protein with C1q. It has been shown that the copy number of *C4*, *C4A*or *C4B*positively correlated with the protein levels of total C4, C4A or C4B, respectively \[[@B7]\]. In our results, individuals with 4, 2, and 2 copies of *C4*, *C4A*or *C4B*have higher risk whereas those with deficiencies of *C4*, *C4A*or *C4B*have lower risk toward GD. One possibility is that a deficiency of complement may lead to ineffective opsonization, lytic activity or impairment of B-cell memory, by which reduce tissue injury \[[@B15]\]. Unfortunately, the mechanisms by which *C4*abnormality contributes to the protection of organ-specific autoimmunity are poorly understood. Nevertheless, whether a potential gene-gene or gene-environment interaction is involved in susceptibility to GD needs to be further investigated \[[@B16]\]. This study provides a substantial amount of data that may help to clarify the role of *C4*genes in this disorder. It is only through investigations of diverse populations that researchers can expect to dissect the complex genetics involved. In addition, functional studies of susceptibility genes using appropriate animal models could allow for an assessment of their role in the disease process.

However, it may play a different regulatory role in systemic autoimmune diseases. Low level of C4 complements in sera has been found in several autoimmune diseases \[[@B17]-[@B21]\]. In addition, the presence of *C4A*null allele that results in partial C4 deficiency have shown to be risk factor for susceptibility in systemic lupus erythematosus (SLE) and the SLE-related renal damage \[[@B7],[@B19]\]. A hypothesis is that complement may participate in the presentation of self-antigens to developing B cells by which protects against responses to self-antigens and subsequence promoting the elimination of self-reactive lymphocytes \[[@B9]\]. The pathogenesis of vitiligo, similar to SLE, is characterized by the destruction of cutaneous melanocytes which due to another antibody-induced hypopigmentation. Experiments in knockout mice have demonstrated that complement deficient can cause the destruction of pigment cells leading to vitiligo-like depigmentation \[[@B21]\]. Our results revealed that deficiency of *C4A*may enhance the development of vitiligo in GD patients, implying exist of an alternative pathway for the deficiency of complement.

What is interesting is that although we explored the relationship of *C4*CNV to GD as well as other GD clinical features, only the lower copies of *C4A*, but not *C4B*, were associated with higher risk of vitiligo. Because it appears that C4A binds to amino group-containing antigens such as immune complex, whereas C4B binds to hydroxyl group-containing antigens such as bacteria, this result may provide another view to support the hypotheses that the pathogenesis of vitiligo may be more relevant to the existence of the immune complex than the pathogen. In addition, recent studies have identified that the risk locus within the major histocompatibility complex region on chromosome 6q may be associated with vitiligo in both Chinese Han population and American population \[[@B22],[@B23]\]. It may be interesting to investigate the gene-gene interaction between *C4*polymorphism and the vitiligo risky locus. Moreover, although confirmation of these results in larger samples is warranted, it would be interesting to further investigate the functional role of *C4A*in the development of vitiligo.

Conclusion
==========

This study provides evidence that the CNV of *C4*, *C4A*or *C4B*may associate with the development of GD and \<2 copies of *C4A*may associate with development of vitiligo in patients with GD. These results may be further estimated for its application on predicting the occurrence of GD and the clinical outcome in patients with GD which might aid in the diagnosis of the disease and the development of therapeutic strategies.
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